Clinical trial · Interventional
A Phase II Study of Radiation Therapy to Treat Refractory Breast Cancer
A Prospective Phase II Study of Radiation Therapy to Treat Refractory Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
For locally advanced or recurrent metastatic breast cancer that is resistant to systemic therapy, radiotherapy (RT) may be considered as the preferred treatment option when the lesion is unresectable, or the patient is not suitable for surgery. This study aim to evelatuate the local control of radical dose RT or new RT technique (such as patially fractionated radiation therapy, SFRT) for the locally advanced or recurrent metastatic breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radical dose radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Radiotherapy
- description
- Radical dose is delivered for the patients. . SFRT is recommended for the patients with bulky tumor (such as ≥ 5cm). SFRT is delivered with 12-20Gy (1 fraction) followed by EBRT with EQD2≥60Gy.
- interventionNames
- Radiation: Radical dose radiotherapy
Primary outcomes (1)
- measure
- Overall Response Rate (ORR)
- timeFrame
- 3 months
Secondary outcomes (5)
- measure
- Overall Response Rate (ORR)
- timeFrame
- 1 month
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; * Locally advanced or recurrent metastatic breast cancer, pathologically confirmed; * At least one extracranial measurable lesion suitable for radiotherapy; * Signature of informed consent form. Exclusion Criteria: * Pregnant or lactation women; * Severe concomitant conditions, including persistent or active infections, symptomatic congestive heart failure, unstable angina pectoris, and serious arrhythmias et al.
References
Publications (0)
Data not yet available